Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

A recent study published in the journal Nature Medicine showed that targeting senescent cells in the retina can be a lasting disease-modifying treatment for diabetic macular edema (DME). The retina is ...

Patients with diabetic macular edema could be treated with brolucizumab with as much effectiveness as aflibercept. There were no clinically meaningful differences in visual outcomes when patients with ...

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. UBX1325 met safety and efficacy endpoints at 24 weeks in ...

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach. What are the ...

Xipere approval was based on data from the phase 3 PEACHTREE trial, which included 160 patients with macular edema associated with anterior-, intermediate-, posterior-, or pan-uveitis. Xipere ® ...

LONDON--(BUSINESS WIRE)--The global diabetic macular edema treatment market 2018-2022 is expected to post a CAGR of more than 1% during the forecast period, according to the latest market research ...

Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the ...

Clearside Biomedical, Inc. announced that the Chinese Center for Drug Evaluation has accepted Arctic Vision's New Drug Application (NDA) for ARCATUS®, a treatment for uveitic macular edema (UME), for ...